Patents Assigned to Genentech, Inc.
  • UCP4
    Publication number: 20120041176
    Abstract: The present invention is directed to novel polypeptides having homology to certain human uncoupling proteins (“UCPs”) and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: September 19, 2011
    Publication date: February 16, 2012
    Applicant: GENENTECH, INC.
    Inventors: Sean Adams, James Pan, Alan Zhong
  • Compounds and methods of use
    Patent number: 8114893
    Abstract: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: February 14, 2012
    Assignees: Genentech, Inc., Abbott Laboratories, The Walter and Eliza Hall Medical Research Institute
    Inventors: Jonathan Bayldon Baell, Chinh Thien Bui, Peter Colman, Danette A. Dudley, Wayne J. Fairbrother, John A. Flygare, Guillaume Laurent Lessene, Chudi Ndubaku, George Nikolakopoulos, Carl Steven Rye, Brad Edmund Sleebs, Brian John Smith, Keith Geoffrey Watson, Steven W. Elmore, Andrew M. Petros, Andrew J. Souers, Peter Czabotar
  • GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY
    Publication number: 20120034609
    Abstract: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: Genentech, Inc.
    Inventor: Robert D. Mass
  • HGF ? chain variants
    Patent number: 8110377
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • Method for treating cartilage disorders
    Patent number: 8110548
    Abstract: The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Yvonne Man-Yee Chen, Ross G. Clark, Andrea G. Cochran, Yves Dubaquie, Paul J. Fielder, Ellen Filvaroff, Henry B. Lowman, Deborah L. Mortensen, Iain C. A. F. Robinson, Nicholas J. Skelton
  • Inhibitors of IAP
    Patent number: 8110568
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Kurt Deshayes, Wayne J. Fairbrother, Bainian Feng, John A. Flygare, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui
  • Transgenic mice expressing humanized VEGF
    Patent number: 8110720
    Abstract: The present invention generally relates to humanized VEGF and non-human transgenic animals expressing it. The transgenic animals are also useful to study VEGF-related therapies.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc
    Inventor: Napoleone Ferrara
  • ANTI-HEDGEHOG ANTIBODIES
    Publication number: 20120028829
    Abstract: The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer.
    Type: Application
    Filed: August 24, 2011
    Publication date: February 2, 2012
    Applicant: Genentech, Inc.
    Inventor: Suzanna J. Scales
  • PRO1120 polypeptides
    Patent number: 8106156
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: January 31, 2012
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J Godowski, Austin L Gurney, Victoria Smith, William I Wood
  • Polypeptides that bind APRIL
    Patent number: 8105603
    Abstract: The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: January 31, 2012
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Darshana Ramesh Patel
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20120022043
    Abstract: The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
    Type: Application
    Filed: May 2, 2011
    Publication date: January 26, 2012
    Applicant: Genentech, Inc.
    Inventors: Jeffrey Blaney, Paul A. Gibbons, Emily Hanan, Joseph P. Lyssikatos, Steven R. Magnuson, Richard Pastor, Thomas E. Rawson, Aihe Zhou, Bing-Yan Zhu
  • Treatment methods using NGF variants
    Patent number: 8101571
    Abstract: NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: January 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Leonard G. Presta, Roman Urfer, John W. Winslow
  • Anti-EphB4 antibodies and methods using same
    Patent number: 8101365
    Abstract: The invention provides anti-EphB4 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: January 4, 2007
    Date of Patent: January 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Yan Wu, Minhong Yan
  • Anti-VEGF antibodies
    Patent number: 8101177
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: January 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Bisamide inhibitors of hedgehog signaling
    Patent number: 8101610
    Abstract: The invention provides inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein ring A, ring B, R1, R2, R3, R4, R5, m and n are as defined herein.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: January 24, 2012
    Assignees: Genentech, Inc., Curis Inc.
    Inventors: Richard A. Goldsmith, Daniel P. Sutherlin, Kirk D. Robarge, Alan G. Olivero
  • IMIDAZOPYRIDINE INHIBITORS OF IAP
    Publication number: 20120015974
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X1, X2, Y, Z R1, R2, R3, R3?, R4, R4?, R5, R6, R6? and n are as described herein.
    Type: Application
    Filed: September 26, 2011
    Publication date: January 19, 2012
    Applicant: Genentech, Inc.
    Inventor: Michael F.T. Koehler
  • IGF-I protein variants for treating IGFBP-1-related disorders
    Patent number: 8097587
    Abstract: IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: January 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Yves Dubaquie, Paul J. Fielder, Henry B. Lowman, Deborah L. Mortensen
  • TAT294 polypeptides
    Patent number: 8097700
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: January 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
  • IMMUNOGLOBULIN VARIANTS WITH ALTERED BINDING TO PROTEIN A
    Publication number: 20120009182
    Abstract: Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.
    Type: Application
    Filed: December 23, 2009
    Publication date: January 12, 2012
    Applicant: Genentech, Inc.
    Inventors: Yik Andy Yeung, Henry B. Lowman
  • PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE
    Publication number: 20120010191
    Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: May 6, 2011
    Publication date: January 12, 2012
    Applicants: GENENTECH, INC., GILEAD CONNECTICUT, INC.
    Inventors: Antonio J.M. BARBOSA, Peter A. Blomgren, Kevin S. Currie, Ravi Krishnamoorthy, Jeffrey E. Kropf, Seung H. Lee, Scott A. Mitchell, Daniel Ortwine, Aaron C. Schmitt, Xiaojing Wang, Jianjun Xu, Wendy Young, Honglu Zhang, Zhongdong Zhao, Pavel E. Zhichkin